Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 12/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268979 | 0.89 | IGF1R (0.43) | ACVR1SMN1; SMN2SYKPAK4 | |
| SCHEMBL1268818 | 0.89 | ACVR1 (0.47) | ACVR1SMN1; SMN2KMT2APAK4 | |
| SCHEMBL1269074 | 0.88 | ACVR1 (0.38) | ACVR1SMN1; SMN2SYK | |
| SCHEMBL25211964 | 0.85 | ACVR1 (0.63) | ACVR1 | |
| SCHEMBL20589842 | 0.85 | ACVR1 (0.63) | ACVR1 | |
| SCHEMBL1269113 | 0.83 | IGF1R (0.49) | ACVR1SYK | |
| SCHEMBL1269220 | 0.80 | IGF1R (0.37) | SMN1; SMN2KMT2A | |
| SCHEMBL20589419 | 0.80 | ACVR1 (0.51) | ACVR1 | |
| SCHEMBL14310680 | 0.79 | ACVR1 (0.73) | ACVR1 | |
| SCHEMBL12314366 | 0.79 | ACVR1 (0.73) | ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | claimed |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | claimed |
| EP-2041138-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | ACVR1 2717/4885SMN1; SMN2 3782/4885ITK 169/4885 |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | ACVR1 2717/4885SMN1; SMN2 3782/4885ITK 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.